Investment firm Euro Pacific Capital Inc. on Monday moved to derail an herbal pharmaceuticals manufacturer’s bid to force Chinese arbitration in a $6 million breach of contract battle, ripping its “misstatements of fact, overactive hyperbole and strained arguments.”

The Connecticut-based firm said that Bohai Pharmaceuticals Group Inc. is required to resolve the dispute in New York courts under jurisdictional and forum provisions laid out in its defaulted promissory notes, not in arbitration before the China International Economic and Trade Arbitration Commission.